|
rs6854845
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
A genome wide association study on Newfoundland colorectal cancer patients' survival outcomes.
|
25866641 |
2015 |
|
rs1525489
|
|
|
0.010 |
GeneticVariation |
BEFREE |
However, after stratification by histology (colon vs. rectum) we found that rs1525489 was associated with increased risk of rectal cancer with a (P<sub>trend</sub> of = 0.0071).
|
28915899 |
2017 |
|
rs17239025
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Four SNPs in FLAP (rs17239025), ALOX12 (rs2073438), and ALOX15 (rs4796535 and rs2619112) were associated with rectal cancer risk at P ≤ 0.05.
|
23404351 |
2013 |
|
rs2853668
|
|
|
0.010 |
GeneticVariation |
BEFREE |
TERT-CLPTM1L rs2853668 also was inversely associated with rectal cancer (OR 0.62, 95% CI 0.43, 0.90).
|
22351525 |
2013 |
|
rs17268122
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The screening of ABCC4 rs17268122 tagSNP and the Mandard tumor response in clinical practice may help to identify patients with different rectal cancer prognosis and contribute to an individualized therapeutic decision tree.
|
28011504 |
2017 |
|
rs266729
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We conclude that the rs12733285C/T genotype and the carriage of the A allele of rs1342387 (A/G or A/A) in ADIPOR1 are the protective factors for CRC, while that rs266729G/C and G allele of ADIPOQ are the risk factors for colon cancer after excluding rectal cancer cases.
|
21749709 |
2011 |
|
rs12733285
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We conclude that the rs12733285C/T genotype and the carriage of the A allele of rs1342387 (A/G or A/A) in ADIPOR1 are the protective factors for CRC, while that rs266729G/C and G allele of ADIPOQ are the risk factors for colon cancer after excluding rectal cancer cases.
|
21749709 |
2011 |
|
rs1342387
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We conclude that the rs12733285C/T genotype and the carriage of the A allele of rs1342387 (A/G or A/A) in ADIPOR1 are the protective factors for CRC, while that rs266729G/C and G allele of ADIPOQ are the risk factors for colon cancer after excluding rectal cancer cases.
|
21749709 |
2011 |
|
rs4994
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Analysis of a subgroup with a higher body mass index showed that the Trp64Arg variant increased the OR (2.63; 95% confidence interval, 1.13-6.11) for colon cancer, but not for rectal cancer, compared with the Trp64 genotype.
|
11706779 |
2001 |
|
rs671
|
|
|
0.020 |
GeneticVariation |
BEFREE |
However, with the rectal cancer analysis, the ORs for high alcohol consumption were greater with 487Glu/Lys genotype compared with Glu/Glu, albeit not.
|
12033531 |
2002 |
|
rs671
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Our study supports that ALDH-2 Glu487Lys polymorphism is associated with significant reduced risks of CRC in population-based samples, and of rectal cancer in males.
|
25573590 |
2015 |
|
rs1126667
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Compared with the 261Arg/Arg genotype, 12-LOX 261Arg/Gln genotype and 261Arg/Gln + Gln/Gln genotypes reduced the risk of rectal cancer by 33% (adjusted OR = 0.67, 95% CI 0.47-0.97, p = 0.03) and 32% (adjusted OR = 0.68, 95% CI 0.49-0.96, p = 0.03), respectively.
|
23715757 |
2013 |
|
rs2073438
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Four SNPs in FLAP (rs17239025), ALOX12 (rs2073438), and ALOX15 (rs4796535 and rs2619112) were associated with rectal cancer risk at P ≤ 0.05.
|
23404351 |
2013 |
|
rs2619112
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Four SNPs in FLAP (rs17239025), ALOX12 (rs2073438), and ALOX15 (rs4796535 and rs2619112) were associated with rectal cancer risk at P ≤ 0.05.
|
23404351 |
2013 |
|
rs776197565
|
|
|
0.010 |
GeneticVariation |
BEFREE |
One SNP, rs3219489:G>C (MUTYH Q324H) seemed to confer an increased risk of rectal cancer in homozygous status (OR=1.52; CI=1.06-2.17).
|
20149637 |
2010 |
|
rs1801516
|
|
|
0.010 |
GeneticVariation |
BEFREE |
No associations were found between the IVS38-8 T/C, 5557 G/A and 5558 A/T polymorphisms and microhaplotypes in the ATM gene with respect to sporadic rectal cancer.
|
12827413 |
2004 |
|
rs1801673
|
|
|
0.010 |
GeneticVariation |
BEFREE |
No associations were found between the IVS38-8 T/C, 5557 G/A and 5558 A/T polymorphisms and microhaplotypes in the ATM gene with respect to sporadic rectal cancer.
|
12827413 |
2004 |
|
rs2227935
|
|
|
0.010 |
GeneticVariation |
BEFREE |
However, we detected a significant association of BLM P868L with an increased rectal cancer</span> risk (odds ratio = 1.29, 95% confidence interval 1.02-1.64 and P = 0.04), suggesting a potential cancer-site specificity.
|
19945966 |
2010 |
|
rs2228545
|
|
|
0.010 |
GeneticVariation |
BEFREE |
BMPR2 rs2228545 was associated with an almost twofold increased risk of rectal cancer.
|
21387313 |
2012 |
|
rs113488022
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Here we report a patient with rectal cancer who carried the novel BRAF mutation VK600-601E, which has analogous molecular functions to those of the conventional BRAF mutation V600E, and may have potential as a prognostic marker for colorectal cancer (CRC).
|
25636897 |
2015 |
|
rs113488022
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Compared with BRAF wild type, BRAF(V600E) was a risk for poor survival (overall survival; 5 years: 62.3% vs 51.6%, P=0.014; HR 1.43, CI 1.07-1.90, P=0.009), especially in rectal cancer (for DSS, HR: 10.60, CI: 3.04-36.92, P<0.001).
|
25973534 |
2015 |
|
rs113488022
|
|
|
0.030 |
GeneticVariation |
BEFREE |
dMMR and BRAF V600E mutations were identified in 31 of 208 (14.9%) and 23 of 211 (10.9%) tumors, respectively. dMMR was more commonly found in patients with primary colon tumors rather than rectal cancer (20.4% vs 7.6%, P =0.01), but there was no difference in MMR status between the right-sided and left-sided colon tumors (20.8% vs 34.6%, P = 0.24). dMMR was associated with early-stage rather than metastatic disease (17.3% vs 0%, P = 0.015).
|
25624727 |
2015 |
|
rs121913377
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Compared with BRAF wild type, BRAF(V600E) was a risk for poor survival (overall survival; 5 years: 62.3% vs 51.6%, P=0.014; HR 1.43, CI 1.07-1.90, P=0.009), especially in rectal cancer (for DSS, HR: 10.60, CI: 3.04-36.92, P<0.001).
|
25973534 |
2015 |
|
rs121913377
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Here we report a patient with rectal cancer who carried the novel BRAF mutation VK600-601E, which has analogous molecular functions to those of the conventional BRAF mutation V600E, and may have potential as a prognostic marker for colorectal cancer (CRC).
|
25636897 |
2015 |
|
rs121913377
|
|
|
0.030 |
GeneticVariation |
BEFREE |
dMMR and BRAF V600E mutations were identified in 31 of 208 (14.9%) and 23 of 211 (10.9%) tumors, respectively. dMMR was more commonly found in patients with primary colon tumors rather than rectal cancer (20.4% vs 7.6%, P =0.01), but there was no difference in MMR status between the right-sided and left-sided colon tumors (20.8% vs 34.6%, P = 0.24). dMMR was associated with early-stage rather than metastatic disease (17.3% vs 0%, P = 0.015).
|
25624727 |
2015 |